Abstract:Targeted protein degradation (TPD) technology has gradually become widespread in the past 20 years, which greatly boosts the development of disease treatment. Contrary to small inhibitors that act on protein kinases, transcription factors, ion channels, and other targets they can bind to, targeted protein degraders could target "undruggable targets" and overcome drug resistance through ubiquitin–proteasome pathway (UPP) and lysosome pathway. Nowadays, some bivalent degraders such as proteolysis-targeting chimeras (PROTACs) have aroused great interest in drug discovery, and some of them have successfully advanced into clinical trials. In this review, to better understand the mechanism of degraders, we elucidate the targeted protein degraders according to their action process, relying on the ubiquitin–proteasome system or lysosome pathway. Then, we briefly summarize the study of PROTACs employing different E3 ligases. Subsequently, the effect of protein of interest (POI) ligands, linker, and E3 ligands on PROTAC degradation activity is also discussed in detail. Other novel technologies based on UPP and lysosome pathway have been discussed in this paper such as in-cell click-formed proteolysis-targeting chimeras (CLIPTACs), molecular glues, Antibody-PROTACs (Ab-PROTACs), autophagy-targeting chimeras, and lysosome-targeting chimeras. Based on the introduction of these degradation technologies, we can clearly understand the action process and degradation mechanism of these approaches. From this perspective, it will be convenient to obtain the development status of these drugs, choose appropriate degradation methods to achieve better disease treatment and provide basis for future research and simultaneously distinguish the direction of future research efforts.

An all-in-one targeted protein degradation platform guided by degradation condensates-bridging bi-specific nanobodies

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design

Targeted protein degradation directly engaging lysosomes or proteasomes

Recent advances in targeted protein degraders as potential therapeutic agents

Targeted protein degradation in drug development: Recent advances and future challenges

Targeted protein degradation: mechanisms, strategies and application

ATNC: Versatile Nanobody Chimeras for Autophagic Degradation of Intracellular Unligandable and Undruggable Proteins

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Polymeric Lysosomal-Targeting Chimeras: Extracellular Targeted Protein Degradation Without Co-opting Lysosome-Targeting Receptors

Novel approaches to targeted protein degradation technologies in drug discovery

Ubiquitin‐Independent Degradation: An Emerging PROTAC Approach?

Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Phase Separation Enhanced PROTAC for Highly Efficient Protein Degradation

Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins

Hydrophobic tag-based protein degradation: Development, opportunity and challenge

Targeted Protein Degradation: Principles, Strategies, and Applications

[Induced degradation of proteins by PROTACs and other strategies: towards promising drugs]

Nanoparticle-mediated delivery of peptide-based degraders enables targeted protein degradation